Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 504

1.

The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.

Breast Cancer Res. 2008;10(3):R53. doi: 10.1186/bcr2108. Epub 2008 Jun 17.

2.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH.

Hum Pathol. 2012 Mar;43(3):364-73. doi: 10.1016/j.humpath.2011.05.005. Epub 2011 Aug 10.

PMID:
21835433
3.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
4.

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J.

Breast Cancer Res Treat. 2006 Sep;99(1):85-90. Epub 2006 Mar 16.

PMID:
16541313
5.

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC.

J Natl Cancer Inst. 2008 May 7;100(9):672-9. doi: 10.1093/jnci/djn123. Epub 2008 Apr 29.

PMID:
18445819
6.

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.

Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ.

Breast Cancer Res. 2007;9(5):R65.

7.

Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer.

Celebiler Cavusoglu A, Kilic Y, Saydam S, Canda T, Başkan Z, Sevinc AI, Sakizli M.

Cancer Sci. 2009 Dec;100(12):2341-5. doi: 10.1111/j.1349-7006.2009.01333.x. Epub 2009 Sep 1.

8.

Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.

Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimäki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A.

Cancer Res. 2008 Jul 15;68(14):5533-9. doi: 10.1158/0008-5472.CAN-07-5288.

9.

Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer.

Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V.

Cancer Lett. 2010 Feb 1;288(1):99-106. doi: 10.1016/j.canlet.2009.06.027. Epub 2009 Jul 19.

PMID:
19619935
10.

Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene.

Deng T, Liu JC, Pritchard KI, Eisen A, Zacksenhaus E.

Clin Cancer Res. 2009 Jan 1;15(1):119-30. doi: 10.1158/1078-0432.CCR-08-1708.

11.

Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.

Tsunoda Y, Sakamoto M, Sawada T, Sasaki A, Yamamoto G, Tachikawa T.

Oncology. 2011;81(5-6):336-44. doi: 10.1159/000334690. Epub 2012 Jan 11.

PMID:
22237177
12.
13.

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.

PMID:
19795205
14.

[Analysis on clone in vitro and tumorigenic capacity in vivo of different subsets cells from the MCF-7 human breast cancer cell line].

Li Z, Liu CP, He YL, Tian Y, Huang T.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jul;39(4):547-9. Chinese.

PMID:
18798490
15.

Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies.

Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M.

Lab Invest. 2009 Aug;89(8):857-66. doi: 10.1038/labinvest.2009.54. Epub 2009 Jun 1.

16.

[Detection of breast cancer stem cells and the expression of key molecules in Hedgehog signaling pathway].

Lu ZH, Jia J, Ren J, Ma B, DI LJ, Song GH.

Beijing Da Xue Xue Bao. 2008 Oct 18;40(5):480-5. Chinese.

17.

Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.

Park SY, Kwon HJ, Choi Y, Lee HE, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH.

Mod Pathol. 2012 Feb;25(2):185-96. doi: 10.1038/modpathol.2011.160. Epub 2011 Oct 28.

18.

Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.

Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J.

J Clin Pathol. 2011 Nov;64(11):937-46. doi: 10.1136/jcp.2011.090456. Epub 2011 Jun 16.

PMID:
21680574
19.

CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.

Pathol Res Pract. 2006;202(8):569-76. Epub 2006 Jul 7.

PMID:
16828238
20.

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.

Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A.

Indian J Med Sci. 2009 Apr;63(4):152-62. doi: 10.4103/0019-5359.50764.

PMID:
19414985

Supplemental Content

Support Center